Alibaba Health Information Technology’s Stock Price Plunges to 4.93 HKD, Witnessing a Sharp 4.46% Drop

Alibaba Health Information Technology (241)

4.93 HKD -0.23 (-4.46%) Volume: 217.61M

Alibaba Health Information Technology’s stock price is currently at 4.93 HKD, experiencing a downturn this trading session by -4.46%, despite a robust trading volume of 217.61M and an impressive YTD percentage change of +48.49%, reflecting its dynamic performance in the market.

Latest developments on Alibaba Health Information Technology

Alibaba Health Information Technology has reported strong financial growth in FY2025, with a significant jump in profit of 62% in the year ended March. The company posted a revenue of RMB 30,598.3 million, showcasing its robust performance amid AI integration and policy support. These positive results have led to notable movements in Alibaba Health Information Tec stock price today, reflecting investor confidence in the company’s future prospects.

A look at Alibaba Health Information Technology Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Alibaba Health Information Technology Limited, an integrated healthcare information and content service provider, has received positive Smart Scores in various categories. With a high Growth score of 5, the company shows promising potential for future expansion and development. Additionally, Alibaba Health Information Tec has demonstrated strong Resilience and Momentum, with scores of 4 in both categories, indicating its ability to withstand challenges and maintain steady progress over time.

Although Alibaba Health Information Tec has room for improvement in terms of Value and Dividend scores, with ratings of 2 and 1 respectively, its overall outlook appears favorable based on the Smartkarma Smart Scores. As an innovative player in the healthcare information industry, Alibaba Health Information Tec is well-positioned to capitalize on its strengths and opportunities for continued growth and success in the long term.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma